As part of its policy of supporting entrepreneurial development, the IPBS will very soon welcome the biotech company G.CLIPS for developing its proof of concept and commercial offer, in collaboration with the Genotoul-PICT platform.
The startup founded by Rosie Dawaliby aims to propose solutions for the research of therapeutic agents targeting membrane proteins in tissue and specific conformation related to pathophysiology.
Rosie Dawaliby, a pharmacology researcher, has studied the effect of the lipid environment on G protein coupled receptors (GPCR) at Stanford, alongside Brian Kobilka (winner of the Nobel Prize in Chemistry in 2012), and at the Université libre de Bruxelles in the team of Cédric Govaerts. She then joined Confo Therapeutics, a Brussels-based start-up specialized in the discovery of compounds and antibodies targeting GPCR.
Rosie Dawaliby's expertise and project are fully in line with the research themes of the IPBS.